Association of genital infections other than human papillomavirus with pre-invasive and invasive cervical Neoplasia

Journal of Clinical and Diagnostic Research

Volumn 10, Issue 2, 2016, Pages XE01-XE06

  Ghosh, Ishita ^a   Mandal, Ranajit ^a   Kundu, Pratip ^b   Biswas, Jaydip ^a  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

^b Murshidabad Medical College   (India)

Author keywords

Candida; Chlamydia; Co infections; Trichomonas vaginalis

Indexed keywords

ARTICLE; CARCINOGENESIS; COLPOSCOPY; CYTOLOGY; DISEASE ASSOCIATION; DOT HYBRIDIZATION; GENITAL TRACT INFECTION; HISTOLOGY; HUMAN; IMMUNOFLUORESCENCE; LATEX AGGLUTINATION TEST; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TRICHOMONAS VAGINALIS; TUMOR INVASION; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

EID: 84956667459     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2016/15305.7173     Document Type: Article

References (74)

1. Zur Hausen H. Human genital cancer: synergism between two virus infections and or synergism between a virus infection and initiating events? The Lancet. 1982;320(8312):1370-72.
2. Abd EI All HS, Refaat A, Dandash K. Prevalence of cervical neoplastic lesions and human papilloma virus infection in Egypt: National cervical screening project. Infectious Agents and Cancer. 2007;2:12.
3. Moss SF, Blaser MJ. Mechanisms of disease: inflammation and the origin of cancer. Nat Clin Pract Oncol. 2005;2(2):90-97.
4. Zur Hussain H. Intracellular surveillance of persisting viral infections. Human genital cancer results from deficient cellular control of papillomavirus gene expression. Lancet. 1986;2(8505):489-91.
5. Gopalkrishna V, Aggarwal N, Malhotra VL, Koranne RV, Mohan VP, et al. Chlamydia trachomatis and human papillomavirus infection in Indian women with sexually transmitted diseases and cervical precancerous and cancerous lesions. Clin Microbiol Infect. 2000;6:88-93.
6. Anttila T, Saikku P, Koskela P, Bloigu A, Dillner J, et al. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA. 2001;285:1.
7. Wallin KL, Wiklund F, Luostarinen T, Angström T, Anttila T, et al. A population based prospective study of Chlamydia trachomatis infection and cervical carcinoma. Inter J Cancer. 2002;101:371-74.
8. Tamim H, Finan RR, Sharida HE, Rashid M, Almani WY. Cervicovaginal co-infections with human papillomavirus and Chlamydia trachomatis. Diagn Microbiol Infect Dis. 2002;43(4):277-81.
9. Castle PE, Escoffery C, Schachter J, Rattray C, Schiffman M, et al. Chlamydia trachomatis, herpes simplex virus 2, and human T-cell lymphotrophic virus type 1 are not associated with grade of cervical neoplasia in Jamaican colposcopy patients. Sex Transm Dis. 2003;30:575-80.
10. Jain M, Gupta C, Kumar M. Sexually transmitted diseases and carcinogenesis. J Obstet Gynecol Ind. 2004;54: 73-76.
11. Smith JS, Bosetti C, Muñoz N, Herrero R, Bosch FX, Eluf-Neto J, et al. IARC multicentric case-control study. Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC Multicentric case – control study. Int J Cancer. 2004;111:431-39.
12. Samoff E, Koumans EH, Markowitz LE, Sternberg M, Sawyer MK, Swan D, et al. Association of Chlamydia trachomatis with persistence of high risk types of Human papillomavirus in a cohort of female adolescents. Am J Epidemiol. 2005;162:668-75.
13. Naucler P, Chen HC, Persson K, You SL, Hsieh CY, et al. Seroprevalence of human papillomavirus and Chlamydia trachomatis and cervical cancer risk: nested case control study. J Gen Virol. 2007;88:814-22.
14. Madeleine MM, Anttila T, Schwartz SM, Saikku P, Leinonen M, et al. Risk of cervical cancer associated with Chlamydia trachomatis antibody by histology, HPV type and HPV cofactors. Int J Cancer. 2007;120:650-55.
15. Zereu M, Zettler CG, Cambruzzi E, Zelmanowicz A. Herpes simplex virus type 2 and Chlamydia trachomatis in adenocarcinoma of the uterine cervix. Gynecol Oncol. 2007;105(1):172-75.
16. Chernesky M, Jang D, Portillo E, Chong S, Smeieja M, Luinstra K, et al. Abilities of APTIMA, AMPLICOR and ProbeTec assays to detect Chlamydia trachomatis and Neisseria gonorrhoeae in PreservCyt ThinPrep liquid – based Pap samples. J Clin Microbiol. 2007;45:2355-58.
17. Engberts MK, Verbruggen BS, Boon ME, van Haaften M, Heintz AP. Candida and dysbacteriosis: a cytologic, population-based study of 100,605 asymptomatic women concerning cervical carcinogenesis. Cancer. 2007;111:269-74.
18. Quint KD, de Koning MNC, Geraets DT, Quint WG, Pirog EC. Comprehensive analysis of Human papillomavirus and Chlamydia trachomatis in in-situ and invasive cervical adenocarcinoma. Gynecologic Oncology. 2009;114:390-94.
19. Safaeian M, Quint K, Schiffman M, Rodriguez AC, Wacholder S, et al. Chlamydia trachomatis and risk of prevalent and incident cervical premalignancy in a population based cohort. J Natl Cancer Inst. 2010;102:1794-804.
20. Valdaan M, Yarandi F, Eftehkar Z, Danvish S, Fathollahi MS, et al. Chlamydia trachomatis and cervical intraepithelial neoplasia in married women in a Middle Eastern community. East Med Health J. 2010;16:304-07.
21. Krashin JW, Koumans EH, Bradshaw-Sydnor AC, Braxton JR, Evan Secor W, Sawyer MK, et al. Trichomonas vaginalis prevalence, incidence, risk factors and antibiotic resistance in an adolescent population. Sex Transm Dis. 2010;37:440-44.
22. Farivar TN, Johari P. Lack of association between Chlamydia trachomatis infectin and cervical cancer – Taqman realtime PCR assay findings. Asia Pacific J Cancer Prev. 2012;13:3701-04.
23. Rodriguez-Cedeira C, Sanchez-Blanco E, Alba A. Evaluation of association between vaginal infections and high risk human papillomavirus types in female sex workers in Spain. ISRN Obstet Gynecol. 2012;2012:240190.
24. Ginocchio CC, Chaplin K, Smith JS, Aslanzadeh J, Snook J, Hill CS, et al. Prevalence of Trichomonas vaginalis and coinfection with Chlamydia trachomatis and Neisseria gonorrhoeae in the United States as determined by the Aptima Trichomonas vaginalis nucleic acid amplification assay. J Clin Microbiol. 2012;50: 2601-08.
25. Ghosh I, Ghosh P, Bharti AC, Mandal M, Biswas J, Basu P. Prevalence of Human Papillomavirus and Co-Existent Sexually Transmitted Infections among Female Sex Workers, Men having Sex with Men and Injectable Drug abusers from Eastern India. Asian Pacific J Cancer Prev. 2012;13:799-802.
26. Silva J, Cerqueira F, Ribeiro J, Sousa H, Osorio T, Medeiros R. Is Chlamydia trachomatis related to human papillomavirus infection in young women of Southern European population? A self-sampling study. Archives of Gynecology and Obstetrics. 2013;288:627-33.
27. Kalantari N, Ghaffari S, Bayani M. Trichomons, Candida and Gardnerella in cervical smears of Iranian women for cancer screening. N Am J Med Sci. 2014;6:25-29.
28. Bellaminutti S, Seraceni S, De Seta F, Gheit T, Tommasino M, Comar M. HPV and Chlamydia trachomatis co-detection in young asymptomatic women from high incidence area for cervical cancer. J Med Virol. 2014;86:1920-25.
29. Zhou H, Jia Y, Shen J, Wang S, Li X, Yang R, et al. Gynecologic infections seen in ThinPrep cytological test in Wuhan, China. Frontiers of Medicine. 2014;8: 236-40.
30. Saleh AM, Abdalla HS, Satti AB, Babiker SM, Gasim GI, Adam I. Diagnosis of Trichomonous vaginalis by microscopy, latex agglutination, diamond’s media, and PCR in symptomatic women, Khartoum, Sudan. Diagnostic Pathology. 2014;9:49.
31. Swartzendruber A, Sales JM, Brown JL, DiClemente RJ, Rose ES. Correlates of incident Trichomonas vaginalis infections among African American female adolescents. Sex Transm Dis. 2014;41:240-45.
32. Chernesky M, Jang D, Gilchrist J, Randazzo J, Elit L, Lytywn A, et al. Ease and Comfort of Cervical and Vaginal Sampling for Chlamydia trachomatis and Trichomonas vaginalis with a New Aptima Specimen Collection and Transportation Kit.J Clin Microbiol. 2014;52:668-70.
33. Jensen KE, Thomsen LT, Frederiksen K, Norrild B, van den Brule A, Iftner T, Kjær SK. Chlamydia trachomatis and risk of cervical intraepithelial neoplasia grade 3 or worse in women with persistent human papillomavirus infection: a cohort study. Sex Transm Infect. 2014;90:550-55.
34. Gunasekera HAKM, Silva KCDP, Prathapan S, Mananwatte S, Weerasinghe G, Abeygunasekera N. Prevalence of Chlamydia trachomatis in women attending sexually transmitted disease clinics in the Colombo district, Sri Lanka. Ind J Pathol Microbiol. 2014;57:55-60.
35. Wilson JD, Robinson AJ, Kinghorn SA, Hicks DA. Implications of inflammatory changes on cervical cytology. BMJ. 1990;300:638-40.
36. Konje JC, Otolorin EO, Ogunniyi JO, Obisesan KA, Ladipo OA. The prevalence of Gardenella vaginalis, Trichomonas vaginalis and Candida albicans in the cytology clinic at Ibadan, Nigeria. Afr J Med Sci. 1991;20(1):29-34.
37. Viikki M, Pukkala E, Nieminen P, Hakama M. Gynaecological infections as risk determinants of subsequent cervical neoplasia. Acta Oncologica. 2000;39:71–75.
38. Shethwala ND, Mulla SA, Kosambiya JK, Desai VK. Sexually transmitted infections and reproductive tract infections in female sex workers. Indian J Pathol Microbiol. 2009;52:198-99.
39. Chakrabarti RN, Dutta K, Sarkhel T, Maity S. Cytological evidence of the association of different infective lesions with dysplastic changes in the uterine cervix. Eur J Gynaecol Oncol. 1992;13(5):398-402.
40. Dalle F, Wächtler B, L’Ollivier C, Holland G, Bannert N. Cellular interactions of Candida albicans with human oral epithelial cells and enterocytes. Cell Microbiol. 2010;12:248-71.
41. Mayer FL, Wilson D, Hube B. Candida albicans pathogenicity mechanisms. Virulence. 2013;4:119–28.
42. Sood S, Kapil A. An update on Trichomonas vaginalis. Indian J Sex Transm Dis. 2008;29:7-14.
43. Preethi V, Mandal J, Halder A, Parija SC. Trichomoniasis. An update. Trop Parasitol. 2011;1:73-75.
44. Frost JK. Trichomonas vaginalis and cervical epithelial changes. Annals of the New York Academy of Sciences. 1962;97:792-99.
45. Zhang ZF, Begg CB. Is Trichomonas vaginalis a cause of cervical neoplasia? Results from a combined analysis of 24 studies. International Journal of Epidemiology. 1994;23:682-90.
46. Gram IT, Macaluso M, Churchill J, Stalsberg H, et al. Trichomonas vaginalis (TV) and human papillomavirus (HPV) infection and the incidence of cervical intraepithelial neoplasia (CIN) grade III. J Cancer Causes Control. 1992;3:231-36.
47. Jatau ED, Olonitola OS, Olayinka AT. Prevalence of Trichomonas infection among women attending antenatal clinics in Zaria, Nigeria. Annals of African Medicine. 2006;5:178-81.
48. Lazenby GB, Taylor PT, Badman BS, Mchaki E, Korte JE, Soper DE, et al. An association between Trichomonas vaginalis and high-risk human papillomavirus in rural Tanzanian women undergoing cervical cancer screening. Clinical Therapeutics. 2014;36:38-45.
49. Zigas V. An evaluation of trichomoniasis in two ethnic groups in Papua New Guinea. Sex Transm Dis. 1977;4:63-65.
50. O Farrell N, Hoosen AA, Kharsany AB, et al. Sexually transmitted pathogens in pregnant women in a rural South African community. Genitourin Med. 1989; 65:276-80.
51. Klouman E, Masenga EJ, Klepp KI, Sam NE, Nyka W, Nyla C, et al. HIV and reproductive tract infections in a total village population in rural Killimanjaro, Tanzania: women at increased risk. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:163-68.
52. Passey M, Mgone CS, Lupiwa S, Suve N, Tiwara S, Lupiwa T, et al. Community based study of sexually transmitted diseases in rural women in the highlands of Papua New Guinea: prevalence and risk factors. Sex Transm Inf. 1998;74:120-27.
53. Bowden FJ, Garnett GP. Trichomonas vaginalis epidemiology: parameterising and analysing a model of treatment interventions. Sex Transm Inf. 2000;76: 248–56.
54. Johnston VJ, Mabey DC. Global epidemiology and control of Trichomonas vaginalis. Current opinion in infectious diseases. 2008;21:56-64.
55. Vishwanath S, Talwar V, Prasad R, Coyaji K, Elias CJ, et al. Syndromic management of vaginal discharge among women in a reproductive health clinic in India. Sex Transm Inf. 2000;76:303-06.
56. Koss LG, Wolinska WH. Trichomonas vaginalis cervicitis and its relationship to cervical cancer a cytohistogical study. Cancer. 1959;12:1171-93.
57. Hirt RP. Trichomonas vaginalis virulence factors: an integrative overview. Sex Transm Infect. 2013;89:439-43.
58. Schautteet K, De Clercq E, Vanrompay D. Chlamydia trachomatis vaccine research through the years. Infectious Diseases in Obstetrics and Gynecology. 2011;2011:963513. http://dx.doi.org/10.1155/2011/963513.
59. Wyrick PB. Chlamydia trachomatis persistence in vitro: an overview. J of Infect Dis. 2010;201:88–95.
60. Abdelsamed H, Peters J, Byrne GI. Genetic variation in Chlamydia trachomatis and their hosts: impact on disease severity and tissue tropism. Future Microbiol. 2013;8:1129–46.
61. Dicker LW, Mosure DJ, Kay RS, Shelby L, Cheek J. An ongoing burden: chlamydial infections among young American Indian women. Maternal Child Health J. 2008;12:25-29.
62. Bosch FX, de Sanjosé S. The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers. 2007;23:213-17.
63. Lehtinen M, Dillner J, Knekt P, Luostarinen T, Aromaa A, et al. Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study. BMJ. 1996;312:537-39.
64. Koskela P, Anttila T, Bjørge T, Brunsvig A, Dillner J, Hakama M, et al. Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer. 2000;85:35–39.
65. Dilner J, Lenner P, Lehtinen M, Eklund C, Heino P, et al. A population – based seroepidemiological study of cervical cancer. Cancer Res. 1994;54:131-41.
66. Paavonen J, Karunakaran KP, Noguchi Y, Anttila T, Bloigu A, et al. Serum antibody responses to the heat shock protein 60 of Chlamydia trachomatis in women with developing cervical cancer. Am J Obstet Gynecol. 2003;189:1287-92.
67. Bułhak-Kozioł V, Zdrodowska-Stefanow B, Ostaszewska-Puchalska I, Makowiak-Matejczyk B, Pietrewicz TM, Wilkowska-Trojniel M. Prevalence of Chlamydia trachomatis infection in women with cervical lesions. Advances in Medical Sciences. 2007;52:179-81.
68. Jha PK, Beral V, Peto J, Hack S, Hermon C, et al. Antibodies to human papillomavirus and to other genital infectious agents and invasive cervical cancer risk. Lancet. 1993;341:1116-18.
69. Bhatla N, Puri K, Joseph E, Kriplani A, Iyer VK, Sreenivas V. Association of Chlamydia trachomatis infection with human papillomavirus (HPV) & cervical intraepithelial neoplasia-A pilot study. Indian J Med Res. 2013;137(3):533-39.
70. Krajowa IDL, Polskie TG. Guidelines for application of molecular tests identifying HR HPV DNA Statement of experts from PGS (PGT) and NCLD (KIDL). Ginekol Pol. 2013;84:395-99.
71. Giorgi Rossi P, Ronco G. The present and future of cervical cancer screening programmes in Europe. Curr Pharma Des. 2013;19:1490-97.
72. Montogomery K, Bloch JR. The human papillomavirus in women over 40: implications for practice and recommendations for screening. J Am Acad Nurse Pract. 2010;22:92-100.
73. Chumduri C, Gurumurthy RK, Zadora PK, Mi Y, Meyer TF. Chlamydia infection promotes host DNA damage and proliferation but impairs the DNA damage response. Cell host and microbe. 2013;13(6):746-58.
74. Paavonen J. Chlamydia trachomatis and cancer. Sex Transm Infect. 2001; 77: 154-56.